<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712959</url>
  </required_header>
  <id_info>
    <org_study_id>TD526</org_study_id>
    <nct_id>NCT00712959</nct_id>
  </id_info>
  <brief_title>Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose</brief_title>
  <official_title>Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect additional immunogenicity and safety data on
      re-dosing with Tdap vaccine (ADACEL®) in a continuing effort to address the public health
      need to establish broader population immunity against pertussis, as well as diphtheria and
      tetanus.

      Primary Objective:

        -  To assess immune response to Tdap vaccine (ADACEL®) one month after booster vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter study to describe the immunological response and safety of
      repeat administration of an adolescent/adult-formulation tetanus-diphtheria-acellular
      pertussis Tdap vaccine (ADACEL®), 10 years following initial administration of Tdap vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection Against Tetanus and Diphtheria Before and After Revaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 0 (pre-vaccination) and 30 post-vaccination</time_frame>
    <description>Diphtheria concentrations were determined by neutralization assay; tetanus concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Seroprotection was defined as anti-tetanus or anti-diphtheria concentrations ≥ 0.1 IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pertussis Geometric Mean Concentrations Post-vaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>Post-vaccination geometric mean concentrations (GMCs) for pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving Booster Response of Anti-Tetanus and Anti-Diptheria Following Revaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>Anti-diphtheria or anti-tetanus booster responses were defined as:
Pre-vaccination antibody concentrations of &lt; 0.1 IU/mL and a post-vaccination levels ≥ 0.4 IU/mL; or a pre-vaccination antibody concentrations of ≥ 0.1 IU/mL to &lt; 2 IU/mL and a 4-fold rise; or pre-vaccination antibody concentrations of ≥ 2.0 IU/mL and a 2-fold response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving Booster Response for Each Anti-Pertussis Antibody Following Revaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
    <description>Booster response for each anti-pertussis antibody was defined as a post-vaccination antibody concentration:
≥ 4 x the Lower limit of quantitation (LLOQ), if the pre-vaccination concentration was &lt; LLOQ; or
≥ 4 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ LLOQ but &lt; 4 x LLOQ; or
≥ 2 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ 4 x LLOQ.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentrations Against Pertussis Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
    <description>Post-vaccination geometric mean concentrations (GMCs) against pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Concentrations Against Tetanus and Diphtheria Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
    <description>Post-vaccination geometric mean concentrations (GMCs) for Diphtheria was determined by neutralization assay; GMCs for tetanus was determined by enzyme-linked immunosorbent assay (ELISA).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-vaccination With ADACEL® 10 Years After a Previous Dose</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, and swelling. Solicited Systemic Reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 - Pain: Incapacitating, : Incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Erythema and Swelling: ≥5 cm; Fever: &gt; 39.0°C, Headache, Malaise, and Myalgia Prevents daily activities.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">769</enrollment>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Diphtheria</condition>
  <arm_group>
    <arm_group_label>Group 1: Previous Tdap or Tdap-IPV Recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Tdap vaccine-naïve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)</intervention_name>
    <description>0.5 ml, IM</description>
    <arm_group_label>Group 1: Previous Tdap or Tdap-IPV Recipients</arm_group_label>
    <other_name>Tdap</other_name>
    <other_name>ADACEL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 2: Tdap vaccine-naïve</arm_group_label>
    <other_name>Tdap</other_name>
    <other_name>Adacel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Received Tdap or Tdap-IPV vaccine in study TD9707 or TD9805.

          -  Never previously received Tdap vaccine and has not received any tetanus-, diphtheria ,
             or pertussis-containing vaccine in the past 10 years.

          -  Participated in TD9707 or TD9805 but does not meet inclusion/ exclusion criteria or
             willing to undergo phlebotomy but not willing to receive Tdap (ADACEL®) vaccine.

          -  Signed Institutional Review Board (IRB)-approved informed consent form

          -  Able to attend all scheduled visits and to comply with all trial procedures

          -  For a woman, a negative urine pregnancy test and the use of effective method(s) of
             contraception, or the inability to become pregnant

        Exclusion Criteria :

          -  Any condition listed as a contraindication in the ADACEL® Canadian product monograph

          -  Any condition which, in the opinion of the investigator, would pose a health risk to
             the subject or interfere with the evaluation of the vaccine

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the investigator

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic (injected or oral) corticosteroid therapy. Individuals on a
             tapering dose schedule of oral steroids lasting less than 7 days may be included in
             the trial as long as they have not received more than 1 course within the last 2 weeks
             prior to enrollment

          -  Febrile illness (temperature ≥ 37.5°C [99.5°F]) at the time of inclusion

          -  History of documented diphtheria, pertussis, or tetanus disease since participation in
             studies TD9707 or TD9805. Or history of documented diphtheria, pertussis, or tetanus
             disease in the last 10 years.

          -  Known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine
             since participation in study TD9707 or TD9805. For Group 2, known or suspected receipt
             of a diphtheria-, pertussis-, or tetanus-containing vaccine in the last 10 years.

          -  Receipt of any vaccine, other than influenza vaccine, in the 28-day period prior to
             Visit 1 or scheduled to receive any vaccine, other than influenza vaccine, in the
             period between Visit 1 and Visit 2. For influenza vaccine only, defer if received in
             the 14 days prior to enrollment or scheduled to receive prior to Visit 2.

          -  Receipt of blood or blood-derived products in the past 3 months

          -  Suspected or known hypersensitivity to any of the vaccine components, or a
             life-threatening reaction after previous administration of the vaccine or a vaccine
             containing the same substances

          -  Unable to attend the scheduled visits or to comply with the study procedures

          -  In females of childbearing potential, known pregnancy or positive serum/urine
             pregnancy test

          -  Breast-feeding woman

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the 4 weeks preceding enrollment. Planned participation in
             another clinical trial during the present trial period

          -  Current alcohol or recreational drug use that may interfere with the subject's ability
             to comply with trial procedures

          -  Thrombocytopenia, bleeding disorder, anticoagulation therapy contraindicating
             intramuscular (IM) vaccination

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  Other events which in the judgment of the investigator would preclude vaccination at
             the time of Visit 1 For Group 3

          -  History of documented diphtheria, pertussis, or tetanus disease since participation in
             study TD9707 or TD9805

          -  Known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine
             since participation in study TD9707 or TD9805.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3C 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivée L, Langley JM, McNeil SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012 Jan 20;30(5):974-82. doi: 10.1016/j.vaccine.2011.11.035. Epub 2011 Nov 21.</citation>
    <PMID>22115634</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2008</study_first_submitted>
  <study_first_submitted_qc>July 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2008</study_first_posted>
  <results_first_submitted>February 18, 2014</results_first_submitted>
  <results_first_submitted_qc>April 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2014</results_first_posted>
  <disposition_first_submitted>March 1, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 16, 2011</disposition_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pertussis</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Acellular pertussis</keyword>
  <keyword>ADACEL®,</keyword>
  <keyword>Tdap vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 26 June 2008 to 27 February 2009 at 7 medical centers in Canada.</recruitment_details>
      <pre_assignment_details>A total of 769 participants who met the inclusion and exclusion criteria were enrolled, 768 were vaccinated and evaluated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
          <description>Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Tdap Vaccine-naïve</title>
          <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="361"/>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="404"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
          <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Tdap Vaccine-naïve</title>
          <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="361"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="768"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356"/>
                    <measurement group_id="B2" value="402"/>
                    <measurement group_id="B3" value="758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.2" spread="14.0"/>
                    <measurement group_id="B2" value="34.6" spread="12.5"/>
                    <measurement group_id="B3" value="33.0" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361"/>
                    <measurement group_id="B2" value="407"/>
                    <measurement group_id="B3" value="768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection Against Tetanus and Diphtheria Before and After Revaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Diphtheria concentrations were determined by neutralization assay; tetanus concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Seroprotection was defined as anti-tetanus or anti-diphtheria concentrations ≥ 0.1 IU/mL.</description>
        <time_frame>Day 0 (pre-vaccination) and 30 post-vaccination</time_frame>
        <population>Anti-tetanus and anti-diphtheria concentrations were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection Against Tetanus and Diphtheria Before and After Revaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Diphtheria concentrations were determined by neutralization assay; tetanus concentrations were determined by enzyme-linked immunosorbent assay (ELISA).
Seroprotection was defined as anti-tetanus or anti-diphtheria concentrations ≥ 0.1 IU/mL.</description>
          <population>Anti-tetanus and anti-diphtheria concentrations were assessed in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-tetanus Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Pertussis Geometric Mean Concentrations Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Post-vaccination geometric mean concentrations (GMCs) for pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Pertussis Geometric Mean Concentrations Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Post-vaccination geometric mean concentrations (GMCs) for pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis Toxoid [n=318, 357]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="105" upper_limit="129"/>
                    <measurement group_id="O2" value="89.2" lower_limit="80.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin [n=324, 380]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="199" upper_limit="231"/>
                    <measurement group_id="O2" value="249" lower_limit="229" upper_limit="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin [n=324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" lower_limit="243" upper_limit="292"/>
                    <measurement group_id="O2" value="216" lower_limit="188" upper_limit="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 [n=324, 378]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779" lower_limit="720" upper_limit="843"/>
                    <measurement group_id="O2" value="1015" lower_limit="894" upper_limit="1154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Booster Response of Anti-Tetanus and Anti-Diptheria Following Revaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Anti-diphtheria or anti-tetanus booster responses were defined as:
Pre-vaccination antibody concentrations of &lt; 0.1 IU/mL and a post-vaccination levels ≥ 0.4 IU/mL; or a pre-vaccination antibody concentrations of ≥ 0.1 IU/mL to &lt; 2 IU/mL and a 4-fold rise; or pre-vaccination antibody concentrations of ≥ 2.0 IU/mL and a 2-fold response.</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Booster Response to Tetanus and Diptheria antigens were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Booster Response of Anti-Tetanus and Anti-Diptheria Following Revaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Anti-diphtheria or anti-tetanus booster responses were defined as:
Pre-vaccination antibody concentrations of &lt; 0.1 IU/mL and a post-vaccination levels ≥ 0.4 IU/mL; or a pre-vaccination antibody concentrations of ≥ 0.1 IU/mL to &lt; 2 IU/mL and a 4-fold rise; or pre-vaccination antibody concentrations of ≥ 2.0 IU/mL and a 2-fold response.</description>
          <population>Booster Response to Tetanus and Diptheria antigens were assessed in the per-protocol population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Tetanus [N = 324, 379]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria [N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Booster Response for Each Anti-Pertussis Antibody Following Revaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Booster response for each anti-pertussis antibody was defined as a post-vaccination antibody concentration:
≥ 4 x the Lower limit of quantitation (LLOQ), if the pre-vaccination concentration was &lt; LLOQ; or
≥ 4 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ LLOQ but &lt; 4 x LLOQ; or
≥ 2 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ 4 x LLOQ.</description>
        <time_frame>Day 30 post-vaccination</time_frame>
        <population>Booster response for each anti-Pertussis antibody was assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Booster Response for Each Anti-Pertussis Antibody Following Revaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Booster response for each anti-pertussis antibody was defined as a post-vaccination antibody concentration:
≥ 4 x the Lower limit of quantitation (LLOQ), if the pre-vaccination concentration was &lt; LLOQ; or
≥ 4 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ LLOQ but &lt; 4 x LLOQ; or
≥ 2 x the pre-vaccination antibody concentration, if the pre-vaccination concentration was ≥ 4 x LLOQ.</description>
          <population>Booster response for each anti-Pertussis antibody was assessed in the per-protocol population.</population>
          <units>Percentage of Particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Pertussis Toxoid [N = 285, 330]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin [N = 324, 379]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin [N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 [N = 324, 371]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentrations Against Pertussis Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Post-vaccination geometric mean concentrations (GMCs) against pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
        <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Pertussis Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Post-vaccination geometric mean concentrations (GMCs) against pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM), were determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis Toxoid [Pre, N = 291, 353]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="12.9" upper_limit="17.6"/>
                    <measurement group_id="O2" value="9.42" lower_limit="8.20" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis Toxoid [Post, N = 318, 357]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="105" upper_limit="129"/>
                    <measurement group_id="O2" value="89.2" lower_limit="80.2" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin [Pre, N = 324, 380]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="31.2" upper_limit="38.7"/>
                    <measurement group_id="O2" value="20.0" lower_limit="17.7" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filamentous Haemagglutinin [Post, N = 324, 380]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="199" upper_limit="231"/>
                    <measurement group_id="O2" value="249" lower_limit="229" upper_limit="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin [Pre, N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="24.4" upper_limit="32.7"/>
                    <measurement group_id="O2" value="8.54" lower_limit="7.41" upper_limit="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertactin [Post, N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266" lower_limit="243" upper_limit="292"/>
                    <measurement group_id="O2" value="216" lower_limit="188" upper_limit="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 [Pre, N = 324, 374]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="111" upper_limit="139"/>
                    <measurement group_id="O2" value="37.8" lower_limit="32.7" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fimbriae Types 2 and 3 [Post, N=324, 378]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779" lower_limit="720" upper_limit="843"/>
                    <measurement group_id="O2" value="1015" lower_limit="894" upper_limit="1154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentrations Against Tetanus and Diphtheria Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Post-vaccination geometric mean concentrations (GMCs) for Diphtheria was determined by neutralization assay; GMCs for tetanus was determined by enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 30 post-vaccination</time_frame>
        <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations Against Tetanus and Diphtheria Antigens Before and Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Post-vaccination geometric mean concentrations (GMCs) for Diphtheria was determined by neutralization assay; GMCs for tetanus was determined by enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Geometric mean concentrations were assessed in the per-protocol population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Tetanus [Pre, N = 324, 379]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.835" lower_limit="0.754" upper_limit="0.924"/>
                    <measurement group_id="O2" value="0.778" lower_limit="0.679" upper_limit="0.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus [Post, N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.79" lower_limit="8.06" upper_limit="9.59"/>
                    <measurement group_id="O2" value="9.64" lower_limit="8.73" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria [Pre, N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.283" lower_limit="0.235" upper_limit="0.341"/>
                    <measurement group_id="O2" value="0.198" lower_limit="0.163" upper_limit="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria [Post, N = 324, 381]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" lower_limit="3.49" upper_limit="4.71"/>
                    <measurement group_id="O2" value="2.74" lower_limit="2.36" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, and swelling. Solicited Systemic Reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 - Pain: Incapacitating, : Incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Erythema and Swelling: ≥5 cm; Fever: &gt; 39.0°C, Headache, Malaise, and Myalgia Prevents daily activities.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
            <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Tdap Vaccine-naïve</title>
            <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Post-vaccination With ADACEL® 10 Years After a Previous Dose</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, and swelling. Solicited Systemic Reactions: Fever (temperature), Headache, Malaise, and Myalgia.
Grade 3 - Pain: Incapacitating, : Incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Erythema and Swelling: ≥5 cm; Fever: &gt; 39.0°C, Headache, Malaise, and Myalgia Prevents daily activities.</description>
          <population>Safety analysis was on all enrolled and vaccinated participants with available reaction data, intent-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain [N = 352, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain [N = 352, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema [N = 351, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema [N = 351, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling [N= 352, 403]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling [N= 352, 403]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever [N = 356, 405]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever [N = 356, 405]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache [N = 350, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache [N = 350, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise [N = 350, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise [N = 350, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia [N = 351, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia [N = 351, 404]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 (post-vaccination) up to 6 months post-vaccination</time_frame>
      <desc>The diary cards for solicited safety data were not returned for some participants; the total number for each event therefore represents those with available data for the indicated event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Previous Tdap or Tdap-IPV Recipients</title>
          <description>Participants received Tdap or Tdap-IPV in a previous study (TD9707 or TD9805)</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Tdap Vaccine-naïve</title>
          <description>Age-balanced Tdap vaccine-naïve participants who received Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-Chiari Malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="361"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="361"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="309" subjects_at_risk="361"/>
                <counts group_id="E2" subjects_affected="341" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Injection Site Pain</sub_title>
                <counts group_id="E1" events="309" subjects_affected="309" subjects_at_risk="352"/>
                <counts group_id="E2" events="341" subjects_affected="341" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Erythema</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="351"/>
                <counts group_id="E2" events="120" subjects_affected="120" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="103" subjects_affected="103" subjects_at_risk="350"/>
                <counts group_id="E2" events="117" subjects_affected="117" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="351"/>
                <counts group_id="E2" events="94" subjects_affected="94" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="31" subjects_affected="30" subjects_at_risk="361"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="211" subjects_affected="211" subjects_at_risk="351"/>
                <counts group_id="E2" events="216" subjects_affected="216" subjects_at_risk="404"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="142" subjects_affected="142" subjects_at_risk="350"/>
                <counts group_id="E2" events="152" subjects_affected="152" subjects_at_risk="404"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="361"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="361"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="407"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

